ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The efficacy and safety of Jinwu Gutong capsule in the treatment of knee osteoarthritis: A meta-analysis of randomized controlled trials

Zhao, Jinlong; Yang, Weiyi; Liang, Guihong; Luo, Minghui; Pan, Jianke; Liu, Jun*; Zeng, Lingfeng*广东省人民医院; 广州中医药大学; 5
Journal of Ethnopharmacology2022-7-15DOI: 10.1016/j.jep.2022.115247
5被引16阅读
引用收藏
分享

摘要

Ethnopharmacological relevance: The Jinwu Gutong (JWGT) capsule is a Chinese patent medicine that is widely used in the treatment of knee osteoarthritis (KOA) and osteoporosis in China and is considered to have the potential for good clinical efficacy.& nbsp;Aim of the study: The purpose of this study was to systematically evaluate the clinical efficacy and safety of JWGT in the treatment of KOA.& nbsp;Materials and methods: We searched the China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, PubMed, Embase and Cochrane Library databases to identify clinical trials that explore the use of JWGT only or JWGT combined with Western drugs (JWGT group) compared with the use of conventional Western drugs (Western drugs group) for the treatment of KOA. The clinical trials, that were retrieved from each database from the inception of the database to December 2021, were screened. We used the risk of bias assessment tool recommended by Cochrane to evaluate the quality of the included literature and RevMan 5.3 software for data analysis.& nbsp;Results: A total of 17 clinical randomized controlled trials (RCTs) were included in this study, with a total of 1930 participants, including 1015 people in the experimental group and 915 people in the control group. The results of the meta-analysis showed that the JWGT group exhibited better efficacy than the Western drug group with respect to WOMAC score (WMD =-6.25, 95% CI =-8.09 to-4.41, P < 0.001), VAS score (WMD =-1.36, 95% CI =-2.17 to-0.55, P = 0.001), KSS score (WMD = 23.01, 95% CI = 21.42 to 24.59, P < 0.001), IL-6 (SMD = -3.30, 95% CI =-4.84 to-1.76, P < 0.001), TNF-alpha (SMD =-1.70, 95% CI =-2.02 to-1.38, P < 0.001). The effective rate (OR = 2.56, 95% CI = 1.83 to 3.57, P < 0.001) and incidence of adverse reactions was significantly lower in the JWGT group than in the control group (OR = 0.13, 95% CI = 0.07 to 0.21, P < 0.001). Subgroup analysis showed that JWGT + NSAIDs had more advantages in regard to efficacy (OR = 2.05, 95% CI = 1.35 to 3.12, P < 0.001), and reducing adverse reactions (OR = 0.10, 95% CI = 0.06 to 0.18, P < 0.001), VAS score (WMD =-1.00, 95% CI =-1.93 to-0.07, P = 0.04), KSS score (WMD = 17.39, 95% CI = 15.39 to 19.39, P < 0.001), WOMAC score (WMD =-2.84, 95% CI =-10.75 to 5.08, P < 0.001), IL-6 (SMD =-1.42, 95% CI = -2.08 to-0.75, P < 0.001) and TNF-alpha (SMD =-1.68, 95% CI =-1.93 to-1.43, P < 0.001) than NSAIDs alone. Compared with hyaluronic acid (HA) alone, JWGT + HA had better clinical efficacy (OR = 3.08, 95% CI = 1.48 to 6.40, P < 0.001). Compared with glucosamine (GS) alone, JWGT + GS significantly reduced the Lequesne index score (WMD =-0.53, 95% CI =-0.85 to-0.21, P = 0.001) and the serum TNF-alpha level (SMD =-1.68, 95% CI =-1.93 to-1.43, P < 0.001), but it had no significant advantage in reducing the serum IL-6 level (SMD =-4.53, 95% CI =-10.13 to 1.07, P = 0.11).& nbsp;Conclusion: JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application. In addition, the application of JWGT combined with NSAIDs, HA or GS can significantly improve the clinical efficacy of the latter agents in KOA treatment.

学科与关键词

关键词
EfficacySafetyKnee osteoarthritisJinwu Gutong capsuleMeta-analysis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Ethnopharmacology
发表日期
2022-07-15
卷期
第 293 卷
页码
115247
DOI
10.1016/j.jep.2022.115247
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82004386, 81873314, 82004383, 81974574]; National key research and development program [2021YFC1712804]; Project of Administration of Traditional Chinese Medicine of Guangdong Province [20201129]; Project of Guangdong Provincial Department of Finance [[2018] 8, [2014] 157]; Medical Science Research Foundation of Guangdong Province [A2020105, B2019091]; Science and Technology Planning Project of Guangzhou [202102010273]; Science and Technology Research Project of Guangdong Provincial Hospital of Chinese Medicine [YN2020MS16, YN2019ML08]

作者

  • Z

    Zhao, Jinlong (第一作者)

    2 · guangzhou univ chinese med · guangdong prov acad chinese med sci

  • Y

    Yang, Weiyi

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 7 位作者收起作者
  • L

    Liang, Guihong

    2 · guangdong prov hosp · guangzhou univ chinese med · guangdong prov acad chinese med sci

  • L

    Luo, Minghui

    2 · guangdong prov hosp · guangzhou univ chinese med

  • P

    Pan, Jianke

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Liu, Jun (通讯)

    guangdong prov acad chinese med sci · 5 · guangzhou univ chinese med

  • Z

    Zeng, Lingfeng (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med · guangdong prov acad chinese med sci

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417